S&P 500   3,566.58 (+0.25%)
DOW   29,409.15 (+0.50%)
QQQ   290.58 (+0.07%)
AAPL   115.76 (-1.35%)
MSFT   209.52 (-0.41%)
FB   266.23 (-1.29%)
GOOGL   1,729.03 (-0.42%)
AMZN   3,107.19 (+0.25%)
TSLA   520.83 (+6.38%)
NVDA   527.99 (+0.86%)
BABA   269.12 (-0.60%)
CGC   23.77 (+0.21%)
GE   10.22 (+4.71%)
MU   63.91 (+4.09%)
AMD   86.70 (+2.43%)
T   28.54 (+0.78%)
NIO   51.36 (+4.28%)
F   8.97 (+2.63%)
ACB   6.99 (-1.96%)
GILD   59.91 (-0.33%)
NFLX   483.43 (-0.99%)
BA   207.19 (+3.79%)
DIS   143.00 (+1.37%)
S&P 500   3,566.58 (+0.25%)
DOW   29,409.15 (+0.50%)
QQQ   290.58 (+0.07%)
AAPL   115.76 (-1.35%)
MSFT   209.52 (-0.41%)
FB   266.23 (-1.29%)
GOOGL   1,729.03 (-0.42%)
AMZN   3,107.19 (+0.25%)
TSLA   520.83 (+6.38%)
NVDA   527.99 (+0.86%)
BABA   269.12 (-0.60%)
CGC   23.77 (+0.21%)
GE   10.22 (+4.71%)
MU   63.91 (+4.09%)
AMD   86.70 (+2.43%)
T   28.54 (+0.78%)
NIO   51.36 (+4.28%)
F   8.97 (+2.63%)
ACB   6.99 (-1.96%)
GILD   59.91 (-0.33%)
NFLX   483.43 (-0.99%)
BA   207.19 (+3.79%)
DIS   143.00 (+1.37%)
S&P 500   3,566.58 (+0.25%)
DOW   29,409.15 (+0.50%)
QQQ   290.58 (+0.07%)
AAPL   115.76 (-1.35%)
MSFT   209.52 (-0.41%)
FB   266.23 (-1.29%)
GOOGL   1,729.03 (-0.42%)
AMZN   3,107.19 (+0.25%)
TSLA   520.83 (+6.38%)
NVDA   527.99 (+0.86%)
BABA   269.12 (-0.60%)
CGC   23.77 (+0.21%)
GE   10.22 (+4.71%)
MU   63.91 (+4.09%)
AMD   86.70 (+2.43%)
T   28.54 (+0.78%)
NIO   51.36 (+4.28%)
F   8.97 (+2.63%)
ACB   6.99 (-1.96%)
GILD   59.91 (-0.33%)
NFLX   483.43 (-0.99%)
BA   207.19 (+3.79%)
DIS   143.00 (+1.37%)
S&P 500   3,566.58 (+0.25%)
DOW   29,409.15 (+0.50%)
QQQ   290.58 (+0.07%)
AAPL   115.76 (-1.35%)
MSFT   209.52 (-0.41%)
FB   266.23 (-1.29%)
GOOGL   1,729.03 (-0.42%)
AMZN   3,107.19 (+0.25%)
TSLA   520.83 (+6.38%)
NVDA   527.99 (+0.86%)
BABA   269.12 (-0.60%)
CGC   23.77 (+0.21%)
GE   10.22 (+4.71%)
MU   63.91 (+4.09%)
AMD   86.70 (+2.43%)
T   28.54 (+0.78%)
NIO   51.36 (+4.28%)
F   8.97 (+2.63%)
ACB   6.99 (-1.96%)
GILD   59.91 (-0.33%)
NFLX   483.43 (-0.99%)
BA   207.19 (+3.79%)
DIS   143.00 (+1.37%)
Log in
LON:DEST

Destiny Pharma plc (DEST.L) Share Forecast, Price & News

GBX 63.90
+0.40 (+0.63 %)
(As of 11/23/2020 02:45 PM ET)
Add
Compare
Today's Range
63
Now: GBX 63.90▼
64
50-Day Range
55
MA: GBX 79.27▼
107.70
52-Week Range
29.10
Now: GBX 63.90▼
115
Volume78,717 shs
Average Volume59,368 shs
Market Capitalization£28.14 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Destiny Pharma plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing XF-73 Nasal that is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal, which is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops XF-70 for ventilator associated pneumonia/cystic fibrosis/bronchiectasis; DPD-207 for eye infections caused by bacteria and fungi; and XF drugs for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. The company has a collaboration agreement with China Medical System Holdings Limited; research collaboration with the University of Southampton for targeting infections in diabetic foot ulcers and cystic fibrosis; research collaboration with the University of Sheffield; research collaboration with Aston University to investigate novel antimicrobial candidates from its XF-drug platform; collaboration with Cardiff University and Tianjin Medical University; and Collaboration with SporeGen Limited to co-develop treatment for COVID-19. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.
Read More
Destiny Pharma plc (DEST.L) logo

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.48 out of 5 stars


Industry, Sector and Symbol

Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolLON:DEST
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.destinypharma.com
Phone+44-1273-704440
Employees16

Debt

Debt-to-Equity RatioN/A
Current Ratio7.56
Quick Ratio7.50

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales£305,906.00
Price / Sales91.98
Cash FlowGBX 11.89 per share
Price / Cash Flow5.37
Book ValueGBX 12.30 per share
Price / Book5.20

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares44,035,400
Market Cap£28.14 million
Next Earnings DateN/A
OptionableOptionable
GBX 63.90
+0.40 (+0.63 %)
(As of 11/23/2020 02:45 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DEST News and Ratings via Email

Sign-up to receive the latest news and ratings for DEST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Destiny Pharma plc (DEST.L) (LON:DEST) Frequently Asked Questions

How has Destiny Pharma plc (DEST.L)'s stock been impacted by the presidential election?

Destiny Pharma plc (DEST.L)'s stock was trading at GBX 107.70 on November 3rd, 2020 when the presidential election occured and Joe Biden was elected president. Since then, DEST stock has decreased by 40.7% and is now trading at GBX 63.90.
View which stocks have been most impacted by the election.

How has Destiny Pharma plc (DEST.L)'s stock price been impacted by COVID-19?

Destiny Pharma plc (DEST.L)'s stock was trading at GBX 35.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, DEST stock has increased by 80.0% and is now trading at GBX 63.90.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than Destiny Pharma plc (DEST.L)?

Wall Street analysts have given Destiny Pharma plc (DEST.L) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Destiny Pharma plc (DEST.L) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Destiny Pharma plc (DEST.L)'s earnings last quarter?

Destiny Pharma plc (DEST.L) (LON:DEST) announced its quarterly earnings results on Thursday, September, 17th. The company reported ($5.50) earnings per share (EPS) for the quarter.
View Destiny Pharma plc (DEST.L)'s earnings history.

Who are some of Destiny Pharma plc (DEST.L)'s key competitors?

Some companies that are related to Destiny Pharma plc (DEST.L) include Medigene AG (MDG1.F) (MDG1), Acasti Pharma Inc. (ACST.V) (ACST), Novoheart (NVH), Aerpio Pharmaceuticals (ARPO), Open Orphan plc (ORPH.L) (ORPH), e-therapeutics plc (ETX.L) (ETX), Pediapharm Inc. (PDP.V) (PDP), OKYO Pharma Limited (OKYO.L) (OKYO), Navidea Biopharmaceuticals (NAVB), Navidea Biopharmaceuticals (NAVB), Cocrystal Pharma (COCP), Sirona Biochem Corp. (SBM.V) (SBM), Armata Pharmaceuticals (ARMP), Armata Pharmaceuticals (ARMP) and CohBar (CWBR).
View all competitors.

What other stocks do shareholders of Destiny Pharma plc (DEST.L) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Destiny Pharma plc (DEST.L) investors own include Dynavax Technologies (DVAX), (AFPO.L) (AFPO), Aldeyra Therapeutics (ALDX), Ares Capital (ARCC), BioCryst Pharmaceuticals (BCRX), BioNTech (BNTX), Centamin plc (CEY.L) (CEY), Countryside Properties PLC (CSP.L) (CSP), Enbridge (ENB) and EQTEC plc (EQT.L) (EQT).

Who are Destiny Pharma plc (DEST.L)'s key executives?

Destiny Pharma plc (DEST.L)'s management team includes the following people:
  • Mr. Neil Robert Clark, CEO & Director (Age 57, Pay $300.43k)
  • Dr. William Guy Love, Founder, Chief Scientific Officer & Director (Age 57, Pay $250.23k)
  • Mr. Shaun Claydon, CFO, Company Sec. & Director (Age 51, Pay $128.03k)
  • Dr. Jesús M González Moreno, Chief Medical Officer

What is Destiny Pharma plc (DEST.L)'s stock symbol?

Destiny Pharma plc (DEST.L) trades on the London Stock Exchange (LON) under the ticker symbol "DEST."

How do I buy shares of Destiny Pharma plc (DEST.L)?

Shares of DEST and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Destiny Pharma plc (DEST.L)'s stock price today?

One share of DEST stock can currently be purchased for approximately GBX 63.90.

How big of a company is Destiny Pharma plc (DEST.L)?

Destiny Pharma plc (DEST.L) has a market capitalization of £28.14 million and generates £305,906.00 in revenue each year. Destiny Pharma plc (DEST.L) employs 16 workers across the globe.

What is Destiny Pharma plc (DEST.L)'s official website?

The official website for Destiny Pharma plc (DEST.L) is www.destinypharma.com.

How can I contact Destiny Pharma plc (DEST.L)?

Destiny Pharma plc (DEST.L)'s mailing address is Sussex Innovation Centre Science Park Square, Falmer, BRIGHTON, BN1 9SB, United Kingdom. The company can be reached via phone at +44-1273-704440.

This page was last updated on 11/23/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.